Russell Anthony S, Gulliver Wayne P, Irvine E Jan, Albani Salvatore, Dutz Jan P
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
J Rheumatol Suppl. 2011 Nov;88:7-19. doi: 10.3899/jrheum.110899.
There is no doubt that patients with immune-mediated inflammatory diseases (IMID) have a significantly impaired quality of life (QOL). Pain and disability often leave these patients helpless and frustrated. The recognition that addressing physical and psychological functioning plays a significant role in an overall treatment approach led to the inclusion of QOL measures as secondary outcomes in clinical trials with IMID patients. To that end, both generic and disease-specific instruments have been utilized. Measurement of health-related QOL (HRQOL) and patient-reported outcomes (PRO) in a controlled manner allows for better understanding of the correlation between different aspects of disease activity and QOL. In addition, the effects of different therapeutic options on HRQOL-related outcomes can be further evaluated. This 3-part section describes key QOL-related complaints of patients with IMID affecting joints, skin, or gut. An overview of the strengths and weaknesses of various commonly used HRQOL instruments is provided. Finally, the influence of anti-tumor necrosis factor-α agents on HRQOL outcomes, as assessed in recent clinical trials, is highlighted.
毫无疑问，免疫介导的炎症性疾病（IMID）患者的生活质量（QOL）显著受损。疼痛和残疾常常使这些患者无助且沮丧。认识到解决身体和心理功能问题在整体治疗方法中起着重要作用，这导致在针对IMID患者的临床试验中将生活质量测量作为次要结果纳入。为此，通用和疾病特异性工具都已被使用。以可控方式测量健康相关生活质量（HRQOL）和患者报告结局（PRO）有助于更好地理解疾病活动不同方面与生活质量之间的相关性。此外，可以进一步评估不同治疗方案对HRQOL相关结局的影响。这三部分内容描述了影响关节、皮肤或肠道的IMID患者与生活质量相关的关键主诉。提供了各种常用HRQOL工具的优缺点概述。最后，重点介绍了近期临床试验评估的抗肿瘤坏死因子-α药物对HRQOL结局的影响。
